Michael Mee, PhD, is a Principal with Amplitude Ventures, Canada’s leading biotechnology and healthcare venture capital fund. Amplitude’s mission is to ensure that the exceptional science Canadian institutions (academic and commercial) are pursuing has an ability to impact patients’ lives at home and abroad. In doing, so we also aim to establish and foster a vibrant entrepreneurial biotech ecosystem in Canada. Michael is also Managing Director of Amplitude’s recently launched venture studio, Pre-Amp. Pre-Amp is a growing team of inventors and entrepreneurs who partner with academics and company builders around the world to advance proof-of-concept data that will enable breakthrough treatments to patients. 

Following his PhD research in Biomedical engineering in George Church’s lab at HMS, Michael worked at Flagship Pioneering in venture creation. His time at Flagship has been focused on the development of two microbiome companies in the agricultural (Indigo) and therapeutics (Kaleido) domains, co-founding and launching a new therapeutic delivery platform and gene therapy company (Cobalt Biomedicine/Sana Therapeutics) and most recently developing new ventures in AI-based drug development and gene editing areas. A long-term goal of his has always been to bring learnings from Boston back home to help contribute to the Canadian biotech ecosystem. To that end, he has recently relocated to Montreal and is excited to be able to achieve that goal along with the growing team at Amplitude.